Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 111Pheochromocytoma 33Carcinoma, Neuroendocrine 33Pituitary Neoplasms 28Thyroid Cancer, Papillary 26Paraganglioma 26Adrenocortical Carcinoma 21Neoplasms 19Gastro-enteropancreatic neuroendocrine tumor 19Thyroid Neoplasms 17Adrenal Gland Neoplasms 16Multiple Endocrine Neoplasia Type 1 14Stomach Neoplasms 13Prostatic Neoplasms 13Pancreatic Neoplasms 13Carcinoid Tumor 13Sarcoma 12Lung Neoplasms 12Breast Neoplasms 12Thyroid Carcinoma, Anaplastic 11Adenoma, Islet Cell 11Small Cell Lung Carcinoma 10Ovarian Neoplasms 10Neuroblastoma 10Neoplasm Metastasis 10Colorectal Neoplasms 10Carcinoma, Hepatocellular 10Brain Neoplasms 10Meningioma 9Esophageal Neoplasms 9

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Lung Neuroendocrine Tumor × Endocrine × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡